Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03699241 · ClinicalTrials.gov registry record · Phase 1
A Randomized, Double-blinded, Placebo-controlled, Dose-escalation Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV Envelope Protein BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in Healthy, HIV-1 Uninfected Adults
A Phase 1 study, sponsored by International AIDS Vaccine Initiative.
- Completed
- Registry status
- Phase 1
- Development phase
- 61
- Enrollment target
NCT03699241 is a Phase 1 study that has completed, run by International AIDS Vaccine Initiative. The registered enrollment target is 61 participants.
The verdict
NCT03699241, a Phase 1 study, has completed, sponsored by International AIDS Vaccine Initiative.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 61 participants
- Enrollment target
Study Summary
This a phase 1 first-in-human clinical trial to evaluate the safety, tolerability, and immunogenicity of BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in up to 60 healthy adult HIV-uninfected volunteers.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL BG505 SOSIP.664 gp140, adjuvanted
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2018-12-03 |
| Est. Completion | 2023-07-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03699241
The ClinicalTrials.gov registry entry for NCT03699241 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is International AIDS Vaccine Initiative, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03699241 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03699241 about?
NCT03699241 is a clinical study titled "A Randomized, Double-blinded, Placebo-controlled, Dose-escalation Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV Envelope Protein BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in Healthy, HIV-1 Uninfected Adults". This a phase 1 first-in-human clinical trial to evaluate the safety, tolerability, and immunogenicity of BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in up to 60 healthy adult HIV-uninfected volunteers.
What is the current status of trial NCT03699241?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 61 participants. The study started on 2018-12-03. Estimated completion is 2023-07-11.
What interventions are being tested in trial NCT03699241?
The interventions under investigation include: Placebo (BIOLOGICAL), BG505 SOSIP.664 gp140, adjuvanted (BIOLOGICAL).
Who is sponsoring clinical trial NCT03699241?
This trial is sponsored by International AIDS Vaccine Initiative, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.